Page last updated: 2024-11-06

3-amino-1,2,4-benzotriazine-1-oxide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3-amino-1,2,4-benzotriazine-1-oxide: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID79470
CHEMBL ID461345
SCHEMBL ID1651160
SCHEMBL ID11856691
MeSH IDM0177092

Synonyms (26)

Synonym
1,2,4-benzotriazin-3-amine 1-oxide
nsc-13158
nsc13158
5424-06-6
3-amino-1,2,4-benzotriazine 1-oxide
CHEMBL461345
3-aminobenzo[e][1,2,4]triazine 1-oxide
1-oxido-1,2,4-benzotriazin-1-ium-3-amine
AKOS004121499
STK792842
3-amino-1,2,4-benzotriazine-1-oxide
3-amino-1,2,4-benzotriazin-1-ium-1-olate
AB1028
AB01330536-02
3-amino-1,2,4-benzotriazine-1-n-oxide
MB00333
SCHEMBL1651160
BBRWGJRKAHEZBG-UHFFFAOYSA-N
1,2,4-benzotriazine-3-amine 1-oxide
SCHEMBL11856691
mfcd00024038
DTXSID30202590
NCGC00336762-01
TQP0606
3-aminobenzo[e][1,2,4]triazine1-oxide
1-oxy-benzo[1,2,4]triazin-3-ylamine

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"133 mmol/kg) significantly enhanced hypoxic cell killing in HT29 tumor xenografts without causing oxic cell killing, and the combination at its maximum tolerated dose was less toxic to hypoxic cells in the retina than was TPZ alone at its maximum tolerated dose."( Selective potentiation of the hypoxic cytotoxicity of tirapazamine by its 1-N-oxide metabolite SR 4317.
Brown, JM; Hay, MP; Hogg, A; Pruijn, FB; Siim, BG; Sturman, JR; Wilson, WR, 2004
)
0.32

Pharmacokinetics

ExcerptReferenceRelevance
" These small species differences in protein binding are unlikely to have any major impact on the extrapolation of pharmacokinetic data from mice to humans."( Development and validation of a sensitive solid-phase-extraction and high-performance liquid chromatography assay for the bioreductive agent tirapazamine and its major metabolites in mouse and human plasma for pharmacokinetically guided dose escalation.
Graham, MA; Robin, H; Senan, S; Workman, P, 1995
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID409716Cytotoxicity against mouse EMT6/KU cells in aerobic condition for 5 hrs measured after 7 to 10 days2008Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18
Synthesis and biological activity of 1-methyl-tryptophan-tirapazamine hybrids as hypoxia-targeting indoleamine 2,3-dioxygenase inhibitors.
AID409717Cytotoxicity against mouse EMT6/KU cells in hypoxic condition for 5 hrs measured after 7 to 10 days2008Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18
Synthesis and biological activity of 1-methyl-tryptophan-tirapazamine hybrids as hypoxia-targeting indoleamine 2,3-dioxygenase inhibitors.
AID409715Inhibition of indoleamine 2,3-dioxygenase in aerobic condition2008Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18
Synthesis and biological activity of 1-methyl-tryptophan-tirapazamine hybrids as hypoxia-targeting indoleamine 2,3-dioxygenase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's9 (69.23)18.2507
2000's4 (30.77)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.57

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.57 (24.57)
Research Supply Index2.64 (2.92)
Research Growth Index4.21 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.57)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]